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Abstract
The glycopeptide fragment CII259–273 from type II collagen (CII) binds to the murine A
q and human DR4 class II Major
Histocompatibility Complex (MHC II) proteins, which are associated with development of murine collagen-induced arthritis
(CIA) and rheumatoid arthritis (RA), respectively. It has been shown that CII259–273 can be used in therapeutic vaccination
of CIA. This glycopeptide also elicits responses from T-cells obtained from RA patients, which indicates that it has an
important role in RA as well. We now present a methodology for studies of (glyco)peptide-receptor interactions based on a
combination of structure-based virtual screening, ligand-based statistical molecular design and biological evaluations. This
methodology included the design of a CII259–273 glycopeptide library in which two anchor positions crucial for binding in
pockets of A
q and DR4 were varied. Synthesis and biological evaluation of the designed glycopeptides provided novel
structure-activity relationship (SAR) understanding of binding to A
q and DR4. Glycopeptides that retained high affinities for
these MHC II proteins and induced strong responses in panels of T-cell hybridomas were also identified. An analysis of all
the responses revealed groups of glycopeptides with different response patterns that are of high interest for vaccination
studies in CIA. Moreover, the SAR understanding obtained in this study provides a platform for the design of second-
generation glycopeptides with tuned MHC affinities and T-cell responses.
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Introduction
The development of therapeutic agents that prevent or even
reverse disease progression in rheumatoid arthritis (RA) is a
challenge in modern drug discovery. RA is an autoimmune disease
that affects 0.5–1% of the population, with clinical features
including chronic inflammation of peripheral joints and subse-
quent destruction of cartilage and bone. The disease has been
genetically linked to the class II Major Histocompatibility
Complex (MHC II) proteins DR1 and DR4 [1]. These proteins
bind peptide antigens forming peptide/MHC II complexes
(pMHC II) that are presented to circulating CD4
+ helper T cells,
which may initiate an immune response upon activation. In this
paper we describe a new methodology, which was applied to the
creation of a glycopeptide library used to probe binding to MHC
II proteins and subsequent T-cell activation in in vitro model
systems of human and murine autoimmune arthritis. Structure-
based virtual screening was used to enrich sets of biologically
active amino acids at two positions in the glycopeptides. The
studied amino acids are crucial for binding to MHC II and
therefore also crucial for the induction of T-cell responses. The
virtual screening was followed by a ligand-based statistical
molecular design (SMD) in the amino acid chemical space to
select balanced sets of peptides optimal for structure-activity
relationship (SAR) analysis.
We use collagen-induced arthritis (CIA) [2], a mouse model
system, to investigate the role of pMHC II complexes and T-cell
activation in RA. Like RA, CIA is genetically linked to expression
of a specific class II MHC molecule, i.e. the A
q protein [3,4]. It has
previously been shown that CII259–273 (1, Figure 1), a
glycopeptide fragment from type II collagen (CII), can be used
as a vaccine to prevent the development of CIA when
administered alone [5] or as a complex with solubilized A
q
protein [6]. Vaccination with the complex also reduces the severity
of arthritis in mice with an established chronic relapsing disease.
Importantly, glycopeptide 1 has also been linked to RA as it is
recognized by T-cell hybridomas generated from transgenic mice
expressing human DR4 and the human CD4 co-receptor [7].
Moreover, it elicits responses from T cells isolated from a cohort of
RA patients [7]. These findings suggest that it may be possible to
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RA patients and thus treat and ultimately cure the disease.
Glycopeptide 1 binds to the A
q protein with the anchor residues
Ile
260 and Phe
263 positioned in the P1 and P4 pockets of A
q
(Figure 2a), respectively, while the GalHyl
264 side chain forms
critical interactions with T-cell receptors (TCRs) [8–11]. In the
present study, the Ile
260 and Phe
263 residues have been exchanged
for (un)natural amino acids. It has previously been shown that
replacing either of these residues with Ala results in strongly
reduced affinities for the A
q protein [9,10]. A CII245–270 peptide
with the residues Ile
260, Ala
261, and Phe
263 exchanged for Ala,
hydroxyproline, and Asp, respectively, has been shown to be a
competitive inhibitor of antigen-presentation by A
q to T cells [12].
Furthermore, structural modifications of 1 with the introduction of
different bioisosteres into the glycopeptide backbone typically
resulted in strongly reduced A
q binding and T-cell responses [13–
15]. In conclusion, the information gained prior to this study
regarding the ternary TCR/pMHC II complexes involving 1 and
A
q [8–10,12–15] shows that the system is sensitive to structural
modifications of the (glyco)peptide, in particular the T-cell
response which is often diminished. This observation prompted
us to adopt a careful design strategy that combines the strengths of
molecular docking and SMD in order to accomplish a set of
glycopeptides that could result in a spread in binding affinities to
MHC II and with maintained or altered T-cell responses. Such
peptides are of interest as candidates for vaccination studies in CIA
and potentially in RA. The glycopeptides were primarily designed
to target the A
q system, but the human DR4 system was also
included in the biological evaluations. When 1 binds to DR4 the
epitope is shifted so that the side chain of Ile
260 is found in the P-3
position on the flanking region of the binding site while Phe
263
occupies the P1 pocket (Figure 2b) [16].
The use of rational structure-based design to develop peptide
and peptidomimetic ligands that bind to MHC II has been
described earlier in several studies [14,15,17–23]. The design
strategy can be based on intuitive decisions guided by crystal
structures or homology models of pMHC II complexes [14,15,17–
21], or it can involve different molecular modeling approaches, e.g.
pharmacophore matching [22], simulated annealing and/or
energy minimizations [18,24], active-site mapping and de-novo
peptide design [23]. A few studies have also been presented where
molecular docking, i.e. a computational method for predicting
binding between a ligand and a protein, has been used in
redocking experiments [25,26] and in affinity prediction protocols
[27]. In the work presented here, we have applied molecular
docking not in retrospect but in the first stage to virtually screen a
large set of peptides for their potential to bind to MHC II (A
q) with
preserved epitopes (aiming for retained T-cell responses). The aim
was to identify sets of amino acids of interest to include at the
anchor positions Ile
260 and Phe
263 in glycopeptide 1.
SMD has been used in ligand-based design of peptides that
interact with various protein targets [28–30], including MHC
proteins [31]. It allows for the identification of amino acid
candidates for incorporation into peptides to generate peptide
libraries with a balanced range of physicochemical properties,
which is important in establishing a reliable SAR. In addition,
SMD allows one to minimize the number of peptides that must be
synthesized, with maintained statistical robustness in the SAR
analysis, when investigating the influence of physicochemical
properties on the peptides’ bioactivity. This cannot be guaranteed
if amino acids have only been changed in one position at a time.
We have applied SMD to the resulting amino acid sets from the
Figure 1. Glycopeptide CII259–273 (1). 1 activates autoimmune T-
cells when presented by the MHC II A
q protein.
doi:10.1371/journal.pone.0017881.g001
Figure 2. Structural models of the complexes between CII259–270 and A
q or DR4. Glycopeptide CII259–270 is bound to the proteins in the
characteristic extended conformation with the galactose moiety pointing out from the protein. a) Comparative model of CII259–270/A
q [14,15]. The
side chains of Ile
260 (in p260) and Phe
263 (in p263) are anchored in the P1 and P4 pockets. P1 is a well-defined, lipophilic pocket of medium size while
P4 is a relatively deep, mainly lipophilic pocket. b) Structural model [15] of the complex between CII259–270 and a crystal structure [88] of the DR4
protein. The side chain of Phe
263 (in p263) is anchored in the DR4 P1 pocket, which is a large, deep and mainly lipophilic pocket. Consequently, Ile
260
(in p260) is found in the P-3 position on the flanking region of the DR4 binding site.
doi:10.1371/journal.pone.0017881.g002
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after synthesis and evaluation, gave us novel, informative, and
reliable SAR regarding glycopeptide binding to A
q and the
subsequent T-cell responses. To the best of our knowledge, the
study presented in this paper is the first to combine the strengths of
molecular docking simulations with SMD to build small but
information-rich peptide libraries as tools for robust SAR analysis.
Methods
Preparation and characterization of peptide virtual
libraries
N
a-Fmoc protected (S)-amino acid derivatives with side chains
suitably protected for Fmoc-based solid-phase peptide synthesis
were selected from commercial producers. This resulted in 105
amino acid derivatives with non-charged side chains, including
both tautomers of His (see File S1). A virtual library of 11025
peptides was constructed from all combinations of the 105 amino
acids at the positions 260 (p260) and 263 (p263) in the sequence
Ac-Ile
260-Ala-Gly-Phe
263-Lys-Gly-Glu-Gln
267-NH2, referred to as
the original peptide. The virtual peptide sequences were based on
the minimal T-cell epitope with Lys
264 to reduce the number of
rotatable bonds in the dockings since the galactose moiety in the
glycopeptide does not significantly affect A
q binding [32].
Tuning of docking software parameters
Software parameters in OMEGA [33] and FRED [34] were
tuned to reproduced the original peptide pose observed in the A
q
comparative model [14]. Design of experiments (DoE) was applied
to investigate the influence of adjustable parameters in FRED on
the outcome of docking, using full factorial parameter designs [35].
The aim was to find parameter settings that would give robust and
acceptable docking results by relating the parameter settings to the
root mean square deviation (RMSD) between the original peptide
pose and the docking poses obtained of the truncated version of 1
(eight amino acids with 68 heavy atoms and 30 rotatable bonds).
The entire tuning process is presented in the File S1.
Virtual screening, refinement and rescoring
The full library of 11025 peptides was docked to the A
q
comparative model [14] using FRED [34], with tuned settings and
a constraint to restrict the positioning of Lys
264 (see File S1). The
docked peptide conformations were pre-generated using OMEGA
[33] with settings tuned according to the findings of Kirchmair
et al. [36] (see File S1).
Geometrical filtering aiming for maintained or altered T-
cell responses. The objective with the study was to design a set
of glycopeptides that bind to A
q with preserved epitope and thus
could elicit a T-cell response. It has been shown that the TCRs are
sensitive to structural modifications of 1 [8,10,13–15]. Thus, we
adopted a filtering step where we investigated the geometrical
similarity of the docking poses of the 11025 peptides and the
original peptide pose. The docked peptides generally exhibited
large variations of the backbone conformations at the non-
modified C-terminus. Hence, we truncated the peptides after
docking to focus the rescoring on the 260–263 fragments (Ac-p260-
Ala-Gly-p263-NH2).Thiswas motivated bythe fact that allpeptides
share the same C-terminus. The similarity in geometry of the
docked pose to the original was assessed in terms of RMSD of the
position of the backbone C and N atoms of two poses, calculated
using MOE [37]. Poses with RMSD,3.0 A ˚ were energy-
minimized in the protein binding cleft using the MMFF94x force
field in MOE. After energy minimization, poses with
RMSD,1.5 A ˚ were rescored (i.e. the binding strengths between
the peptides and A
q were re-calculated) with the Shapegauss [38],
Plp [39], Chemgauss2, Chemgauss3, Chemscore [40], Screenscore
[41], and Goldscore [42] scoring functions. Goldscore scoring
values were multiplied by 21 for the purpose of comparison with
the other scoring functions, with a large negative value
corresponding to a high rank.
Consensus scoring of individual amino acids aiming for
binding to A
q. The rescoring of the peptides matching the
geometrical criteria (see above) was performed to single out
peptides with likeliness to display moderate to strong binding to
A
q. A consensus scoring strategy [43,44] was adopted to reduce
the dependency on the individual selected scoring functions
[41,45–47]. Consensus scoring can be performed in various ways
[44], including multivariate analysis [48,49], which is the basic
strategy we have used here. The novelty in our approach is that we
do a statistical-based consensus scoring evaluation for the two
varied p260 and p263 separately – not on the full peptides. This
methodology allow for a selection of sets of amino acids for each of
the two varied positions separately that in the next step could be
submitted for SMD based on physicochemical properties.
The docking score values for the 260–263 fragments were used
to extract information of how well the individual amino acids in
p260 and p263 fitted in the A
q binding site. The following
statistical measures were used for each of the amino acids at the
two positions; the frequency (i.e. the number of times an amino
acid occurred in the culled set of peptides), the best score-value,
the average score, and the standard deviation of the score values
for each of the used scoring functions. The rescoring thus resulted
in two matrices (one for each varied position) where amino acids
present in the culled set of peptides were described by 22
parameters - one frequency parameter, and three measures (best
score, mean score and standard deviation) times seven scoring
functions (Shapegauss [38], Plp [39], Chemgauss2, Chemgauss3,
Chemscore [40], Screenscore [41], and Goldscore [42]). The
extracted data was visualized with principal component analysis
(PCA, see below) to facilitate interpretation and selection. Thus,
amino acids selected on the basis of this analysis were highly
ranked, had low standard deviations, and appeared frequently in
highly scored peptides.
SMD of glycopeptides
Amino acids selected by the consensus scoring strategy, i.e.
highly ranked amino acids, were physicochemically characterized
by 1D, 2D, and internal coordinate dependent 3D (i3D) molecular
descriptors using MOE [37] (see File S1). PCA was used to extract
the main principal molecular properties of the two sets of amino
acids (p260 and p263, respectively). The resulting principal
properties (i.e., the score plots and score vectors) were then used
in the selection of amino acids to include in the final set of
glycopeptides. Amino acids were selected for p260 and p263 from
the respective score plots (the first three principal components) to
assure a spread in the chemical diversity that potentially would
lead to a spread in biological response and thus enhance the SAR
analysis. In this screening stage of the project (i.e., when little was
known about the binding preferences of p260 and p263) we
decided to include a higher number of amino acids for each
position than what was afforded by resource restrictions set by the
synthesis if all combinations were to be made. Thus, a final
selection of peptides for synthesis was made based on all amino
acid combinations (of selected amino acids for p260 and p263)
using D-optimal design [50,51] (see the section on Design of
experiments). This small set of glycopeptides contained statistically
balanced combinations of the selected amino acids forming a base
for a robust SAR analysis. The selected amino acids for p260 and
Glycopeptides Used to Investigate Multiresponses
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variables) used in subsequent SAR models.
Principal component analysis
PCA [52,53] was used to compress and visualize amino acid
descriptor data, amino acid docking score values and biological
response data by extracting the main variation (i.e. principal
properties) in the data by calculating the principal components
(PCs) and plotting their scores and loadings. The data were mean-
centered and scaled to unit variance prior to their use in model
calculations. The quality of the model was determined from the
proportion of the variation in the original data explained by the
model (the cumulative sum of squares of the entries (R
2X(cum))
and cross-validated cumulative Q
2 (the cumulative Q
2(cum) across
all PCs)) [54]. Potential outliers were identified using a distance-to-
model (DModX) plot. PCA modeling was performed using the
Evince software package [54].
Design of experiments
Factorial designs were employed in the parameter tuning
process (see File S1) and D-optimal designs were employed to
ensure that the selection of glycopeptides contained physicochem-
ical diversity in the introduced amino acids in p260 and p263. D-
optimal design [50,51] allows for the selection of a subset from a
larger collection of molecules such that the subset spans a given
property space as thoroughly as possible. Federov’s algorithm [55],
as implemented in the MODDE software package [56], was used
where a D-optimal selection was performed in the PCA property
space (the first four score vectors) on combinations of all amino
acids selected from PCA score plots (see SMD of glycopeptides)
resulting in a final subset of glycopeptides that exhibited
physicochemical diversity.
Relating molecular structure to biological activity using
PLS
Partial least square projections to latent structure (PLS)
regressions [57,58] were calculated to interpret the individual
amino acids effect on binding to A
q or DR4. PLS was used to
correlate the indicator variables (i.e., the qualitative description) of
the amino acids in p260 and p263 with a response in a Y matrix,
i.e. % inhibition (at 100 mM and 500 mM for A
q and DR4,
respectively). Here, the peptides were described in terms of the
presence or absence of a specific amino acid in p260 and p263.
Hence, PLS was used to examine the relationship between 14
variables (seven amino acids in p260 and seven amino acids in
p263) and the % inhibition. PLS regression coefficients were
analyzed to identify amino acids that resulted in high or low
activity. The magnitude of the coefficients was plotted in bar
diagrams to visualize the effect of the investigated amino acids.
Large positive coefficient indicated that an amino acid was
beneficial for high affinity at a specific position while large negative
coefficients indicated non-beneficial amino acids. The quality of
the model was assessed in terms of the sum of squares of entries for
Y (R
2Y) and cross-validation leave-one-out (Q
2(cum)). The model
validity (i.e. presence of chance-correlations between the variables
and the responses) were determined via 100 permutation
experiments [59,60]. PLS calculations were performed using the
SIMCA software package [61].
Molecular dynamics simulations
MD simulations of A
q/glycopeptide complexes were performed
to investigate if structural or dynamic differences observed in the
A
q/glycopeptide complexes (i.e., the presented epitope) could be
linked to the T-cell responses. The initial atomic coordinates were
taken from the A
q comparative model [14] in complex with the
CII259–270 glycopeptide [15]. Only the a1 and b1 domains of A
q
(i.e. residues a4–a84 and b3–b94) were taken into account in the
molecular dynamics (MD) simulations [62]. The side chains of
p260 and p263 in the CII259–270 glycopeptide were mutated
manually to give the glycopeptides 6, 7, and 9, respectively, and
the complexes were energy minimized in two steps using
MacroModel within Maestro [63]. First, the complexes were
minimized with the protein backbone atoms constrained with a
force constant of 100 kJ*mol
21*A ˚ 2 and the maximum number of
iterations set to 1000. Second, minimization was performed
without any constraints and the maximum number of iterations set
to 5000. All other parameters were at their default settings. The
Desmond [64,65] software implemented in Maestro [63] was used
for preparing the input structure files for the system while the MD
simulation were run using the Desmond MD code implemented
on the High Performance Computing Center North (HPC2N)
[66]. The minimized complexes were neutralized by adding
counter ions (Na
+) and then solvated using a cubic box shape with
a layer of TIP3P water molecules and a salt concentration of
0.15 M NaCl. The distance between the edges of the box and the
closest atom in the complex was 15 A ˚. OPLS-AA force field
parameters assigned by Maestro were used in the simulations. The
model systems were relaxed prior to the simulations using a default
relaxation protocol in Maestro that includes both restrained and
unrestrained minimizations followed by four short MD simulations
where restraints were gradually removed. A NVT simulation of
18 ns was then performed at 300 K and a recording interval of
two ps for both the trajectory and the energy. All other parameters
were at their default settings.
General procedure for solid-phase glycopeptide
synthesis
Glycopeptides 2–21 were synthesized on Tentagel-S-PHB-
Thr(tBu)-Fmoc resin (40 mmol, 0.26 mmol/g) in mechanically
agitated reactors. All couplings were performed in DMF and
reagent solutions were added to the reactors manually. The indane
derivative (2-aminoindane-2-carboxylic acid) is abbreviated to Aic.
N
a-Fmoc amino acids with the following protecting groups were
used: tert-butyl for Thr, Glu, and Tyr, triphenylmethyl (Trt) for Gln,
tert-butoxycarbonyl (Boc) for Lys. N
a-Fmoc amino acids (4 equiv)
were activated with 1-hydroxybenzotriazole (HOBt, 6 equiv) or 7-
aza-1-hydroxybenzotriazole (HOAt, 6 equiv) and 1,3-diisopropyl-
carbodiimide (DIC, 3.9 equiv). (5R)-N
a-(Fluoren-9-ylmethoxycar-
bonyl)-N
e-benzyloxycarbonyl-5-O-(2,3,4,6-tetra-O-acetyl-b-D-galac-
topyranosyl)-5-hydroxy-L-lysine [14,67] (1.5 equiv) was activated
with 7-aza-1-hydroxybenzotriazole (HOAt, 3 equiv) and 1,3-
diisopropylcarbodiimide (DIC, 1.5 equiv). All coupling reactions
were monitored using bromophenol blue [68] as an indicator.
The Fmoc protecting group was removed by 20% piperidine in
DMF for 10 min. After final Fmoc deprotection, the resin was
washed with CH2Cl2 several times and dried under vacuum.
Cleavage of the glycopeptide from the resin and deprotection of
acid labile protecting groups was achieved by treatment with
trifluoroacetic acid/H2O/thioanisole/ethanedithiol (35:2:2:1,
16 mL) for 3 h at 40uC. The resin was filtered off and washed
with acetic acid, and the filtrate was concentrated under reduced
pressure. The crude peptide was dissolved in acetic acid and
concentrated under reduced pressure several times until the
concentrated crude peptide was dry. The crude peptide was
precipitated, washed with cold anhydrous diethyl ether and
lyophilized from a mixture of water and acetic acid (6:1). It was
then purified by preparative reversed-phase HPLC (Beckman
Glycopeptides Used to Investigate Multiresponses
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at 214 nm) using a Supelco DiscoveryH Bio Wide Pore C18
column (250621.2 mm, 5 mm) and a linear gradient of
0%R100% acetonitrile (0.1% TFA) in H2O (0.1% TFA) over
60 min. For analytical reversed-phase HPLC a Supelco Dis-
coveryH Bio Wide Pore C18 column (25064.6 mm, 5 mm) was
used instead, with a flow-rate of 1.5 mL/min. After lyophilization,
the glycopeptides were deacetylated by treatment with NaOMe in
MeOH (20 mM, 1 mL/mg peptide) for 2–3 h at room temper-
ature with monitoring by analytical reversed-phase HPLC. The
solution was neutralized by the addition of acetic acid and
concentrated under reduced pressure. The residue was purified
using reversed-phase HPLC using the conditions described above
followed by lyophilization. The final glycopeptide products were
$95% pure as determined by analytical reversed-phase HPLC.
The masses of the peptides were determined by MALDI-TOF
mass spectrometry (see File S1).
MHC-binding assay
The binding of the glycopeptides to A
q or DR4 was determined
relative to a biotinylated marker peptide in a competitive
inhibition assay performed essentially as described elsewhere
[10,69]. Briefly, a mixture of a fixed concentration of purified
soluble recombinant MHC II molecules (A
q assay: 0.5 mMA
q;
DR4 assay: 1 mM DR4), biotinylated marker peptide at 3 mM( A
q
assay: CII259–273-bio with Lys
264; DR4 assay: CLIP-bio with
CLIP sequence KPVSKMRMATPLLMQALPM), and various
concentrations of competitor glycopeptides 1–21 (A
q assay: 0, 4,
20, 100, 500 and 2500 mM; DR4 assay: 0, 0.8, 4, 20, 100 and
500 mM) was incubated in PBS containing a protease inhibitor
cocktail (Complete
TM, Boehringer, Mannheim, Germany) at room
temperature for 48 h. This mixture (100 mL) was transferred to
mAb precoated microtiter assay plates, prepared as described
below, and incubated at room temperature for 2 h or at 4uC
overnight to capture the MHC II molecules. The plates were
washed with PBS containing 0.1% Tween 20 to remove excess
peptides and the amount of bound biotinylated marker peptide
was detected and quantified by the dissociation-enhanced
lanthanide fluoroimmunoassay (DELFIAH) system based on the
time-resolved fluoroimmunoassay technique with europium-la-
beled streptavidin (Wallac, Turku, Finland), according to the
manufacturer’s instructions. The A
q and DR4 experiments were
performed in triplicate and duplicate, respectively. Results were
reported as % inhibition at a specific concentration since the
concentration interval did not support a full dose-response curve,
and hence no IC50 values were determined. Microtiter assay
plates precoated with mAB were prepared by incubation with
10 mg/mL mAb (A
q assay: Y3P 10 mAb; DR4 assay: L243 mAb)
at room temperature for 2 h or at 4uC overnight and blocked with
PBS containing 2% low fat milk.
T-cell activation assay
A
q [13,70] and DR4[7,8] restrictedT-cell hybridomas were used
that have been generated previously as reported in the cited
literature references. IL-2 production by T-cell hybridomas
following incubation with antigen and A
q- or DR4-expressing
antigen-presenting spleen cells was measured in 96-well flat-bottom
microtiter plates essentially as described elsewhere [71], but with
slight modifications. Briefly, T-cell hybridoma cells (5610
4) and A
q-
or DR4-expressing syngeneic spleen cells (5610
5) were co-cultured
with various concentrations of glycopeptides 1–21 (0, 0.01, 0.048,
0.24, 1.2, 6.0, 30, and 150 mM) in a total volume of 200 mL. After
24 h, 100 mL portions of the supernatants were removed, frozen to
kill any transferred T cell hybridomas, and assayed for IL-2
production by a sandwich ELISA (capturing mAb, purified rat anti-
mouse IL-2; detecting mAb, biotin rat anti-mouse IL-2; PharMin-
gen, Los Angeles, CA) using the DELFIAH system (Wallac, Turku,
Finland)accordingtothemanufacturer’sinstructions.Recombinant
mouse IL-2 was used as a positive control.
Results
A set of 20 glycopeptides was designed using the two-step
process consisting of structure-based virtual screening and ligand-
based SMD. In the first design stage, docking was applied as a
filter to single out peptides from a virtual library with likeliness to
bind to A
q with a preserved epitope and thus elicit T-cell
responses. In the second step, amino acids identified as potential
binders were used as a basis for SMD, and a physicochemically
diverse subset of amino acid combinations was selected and
incorporated at positions p260 and p263 in glycopeptide 1.
Structure-based virtual screening of glycopeptides
The virtual library of 11025 anchor-modified analogues of 1,
that included all combinations of 105 amino acids in p260 and
p263, respectively, was evaluated in a virtual screening against A
q
using FRED [34] with the tuned docking software settings. The
geometrical filtering of the docked peptides resulted in 1540 of the
11025 peptides that were considered to have a peptide backbone
geometrically similar to the original peptide, and thus potentially
could present a similar pMHC epitope to the T cells. The 260–263
fragments of these 1540 anchor-modified peptides were subjected
to rescoring using seven different scoring functions to estimate the
strength of their interaction with A
q.
The adopted consensus scoring approach based on PCArevealed
46 and 52 amino acid substitutions at p260 and p263, respectively,
that resulted in highly ranked peptides in the virtual screening
(Figure 3 and File S1). The scoring ranks of individual peptides were
translated into estimates of the contributions of specific amino acids
to the binding (the frequency, the best score, the mean score and the
standard deviation for the seven scoring functions - see Methods for
details). The PCA had an R
2X of 0.82 and Q
2 of 0.75 and loading
and score plots for the re-scoring values of the amino acids are
shown in Figure 3. Each dot in the score plot corresponds to a
unique amino acid present in at least one of the 1540 peptides that
remained after the backbone culling steps. The position of each
amino acid inthe scoreplot is correlated to itsdockingscorevalue (a
low scoring function value corresponds to a high rank) and
frequency of occurrence (i.e., how often that specific amino acid
occurred in the culled set of peptides) which are visible in the
loading plot in Figure 3a. Hence, amino acids situated to the left in
the score plot in Figure 3b were scored highly by the scoring
functions and appeared frequently in the 1540 peptides. These
amino acids, which are colored green/blue in the score plot (46 and
52 for p260 and p263, respectively, see File S1), were considered to
be likely to have affinity for the A
q anchoring pockets and were
selected for use in the ligand-based glycopeptide design. Notably,
the amino acids Ile and Phe at p260 and p263, respectively, present
inglycopeptide1,wereinthehighlyscoredgroup(Figure3b).Inthe
case of p260, the amino acids predicted to confer a low affinity for
A
q (shown on the right in Figure 3b) were either smaller or
considerably larger than Ile. For p263, the amino acids associated
with low affinity were small and/or aliphatic (e.g. Ile) or were
considerably more sterically demanding than Phe (e.g. biphenyls).
Ligand-based SMD of glycopeptides
The two selected sets of amino acids for p260 and p263,
respectively, with potential to fit the A
q binding site and to induce a
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process to create a set of glycopeptides with physicochemically
diverse amino acids in p260 and p263 optimal for SAR analysis.
The physicochemical descriptor data of the 46 and 52 selected
amino acids in p260 and p263, respectively, were compressed in
two PCA models to identify the main differences and similarities
in the amino acids’ physicochemical features based on their
principal properties. The two models had R
2X of 0.82 and 0.79,
and Q
2 of 0.73 and 0.67 for p260 and p263, respectively. The
principal properties of the p260 and p263 amino acids are shown
in the score plots of the three first PCs (Figure 4). For the amino
acids selected to fit into the P1 pocket, the principal properties
(Figure 4a–b) corresponded to variations in size (e.g., volume,
vdW area, molar refractivity), hydrophobicity (e.g., logP, number
of hydrogens), and flexibility (KierFlex). The principal properties
(Figure 4c–d) of the amino acids selected to fit the P4 pocket
corresponded to variation in size (e.g. volume, vdW area,
rotatable bonds), hydrophobicity (e.g., logP, polar surface areas),
and density, respectively. Scores and loading plots for the
remaining significant PCs for the p260 and p263 amino acids are
presented in the File S1.
Seven amino acids were selected for p260 and p263,
respectively; their side-chains are shown in Figure 5. The selected
amino acids exhibit a range of physicochemical properties (i.e.,
size, hydrophobicity, flexibility and density), while still being in
vicinity to the amino acid present in the non-modified glycopep-
tide. The seven amino acids for p260 and p263, respectively, gave
rise to 49 theoretical glycopeptides; statistical design was used to
select 20 of these as physicochemically representative peptides for
synthesis. Importantly, all of the p260 and p263 amino acids were
represented in at least two, and more commonly three, of the 20
peptides, making it possible to draw statistically significant SAR
conclusions regarding the effect of individual amino acids and of
specific combinations of amino acids in each position.
Glycopeptide synthesis
The glycopeptides 2–21 (Figure 5) with different amino acids in
positions p260 and p263 were synthesized using Fmoc-based solid-
phase peptide synthesis under standard conditions. After cleavage
from the solid support and purification by reversed-phase HPLC
the galactose moieties were deacetylated by treatment with
methanolic sodium methoxide. Final purification by reversed-
phase HPLC then afforded 2–21 in 26–51% overall yield based on
the capacity of the resin. All of the glycopeptides had a purity of
$95% according to analytical reversed-phase HPLC and their
structures were confirmed by MALDI-TOF mass spectrometry.
Binding to A
q
The binding of glycopeptides 1–21 to A
q was evaluated using a
competitive ELISA-based assay in which the glycopeptides, in a
range of concentrations, were incubated with recombinant soluble
A
q protein and a fixed concentration of a biotinylated marker
peptide. Of the 20 designed glycopeptides, 11 were classified as
actives in a preliminary run and were included in a second run
where dose-dependent inhibition curves were obtained (Table 1
and File S1). The inhibitory effects of the anchor-substituted
glycopeptides ranged from 20–87% at 100 mM, compared to 90%
inhibition for the non-modified 1. Two glycopeptides (i.e. 2 and 4)
were found to have comparable affinity for A
q to that of the non-
modified 1 while the other nine glycopeptides that also bound to
A
q displayed 20–55% inhibition. Five out of the seven selected
amino acids for p260 and p263, respectively, displayed binding to
A
q and the SAR analysis of the A
q glycopeptide binding data
revealed structural elements within the modified amino acids that
were important for binding.
The SAR analysis was facilitated by the linear PLS-regression
model correlating the presence of a specific amino acid in p260
and p263 to the affinity of the peptides for A
q (with model statistics
R
2Y of 0.83, Q
2 of 0.52). Permutation experiments indicated a low
Figure 3. PCA loading and score plots of amino acids score values. a) Loading plot of mean scoring values, standard deviations, top scoring
values and frequency of appearance of amino acids present in the docked peptides. b) Score plot of amino acids and their separation due to
differences in scoring results. Colored markings indicate selected amino acids. Green dots and blue crosses correspond to amino acids in p260 and
p263, respectively, while the red dot and cross correspond to the original amino acids in p260 and p263, respectively.
doi:10.1371/journal.pone.0017881.g003
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(Figure 6) provided a direct interpretation of the effect that the
different amino acids had on the binding to the MHC II proteins.
P1 binding preferences. P1 in the A
q binding site is a
medium-sized and relatively lipophilic pocket that accommodates
Ile
260 of the non-modified 1, as shown in Figure 2. Analysis of the
coefficient values from the PLS regression model based on the A
q
binding data clearly showed that Ile was the preferred amino acid
in p260 (upper plot in Figure 6). Accordingly, glycopeptides 2 and
4, which both contained Ile in p260, were the only anchor-
modified glycopeptides that had comparable A
q affinity to that of
1 (Table 1). As reflected in the A
q coefficients in Figure 6,
introduction of either larger side chains, e.g. homoleucine (cf. 5
with 2, 7 with 4 in Table 1) and cyclohexylglycine (cf. 12 with 3),
or a smaller side chain, i.e. cyclopropylalanine (cf. 6 with 9), led to
reduced A
q binding. Substitution of Ile with 4-thiazolylalanine also
led to significant loss of A
q affinity (cf. 14 with 1). Gln and the
indane derivative that had the most negative A
q coefficients
Figure 4. Score plots from PCA models based on amino acid physicochemical properties. Principal properties that dominate each PC are
indicated by the axes. Red dots indicate selected amino acids. Green dots and blue crosses indicate unselected amino acids. a) PC1 vs. PC2 for the
p260 amino acids. b) PC2 vs. PC3 for the p260 amino acids. c) PC1 vs. PC2 for the p263 amino acids. d) PC2 vs. PC3 for the p263 amino acids.
doi:10.1371/journal.pone.0017881.g004
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acids examined in p260, Ile was found to be the best choice
suggesting that the glycopeptide side chain inserted in the P1
pocket should preferably be of moderate size and bulkiness,
aliphatic, and flexible.
P4 binding preferences. The P4 pocket in the A
q binding
site has a larger volume and is deeper than the P1 pocket and it
accommodates the side chain of Phe
263 of the non-modified 1,a s
shown in Figure 2. Interestingly, the coefficient values in the PLS
regression model based on the A
q binding data suggest that three
of the introduced substitutions in p263 were more beneficial for
A
q binding than the original Phe (upper graph of Figure 6).
These were the 4-fluorophenylalanine (cf. 2 with 1 in Table 1), 4-
thiazolylalanine (cf. 4 with 1), and m-methylphenylalanine (cf. 15
with 14), which all had larger positive coefficients than Phe. 3-
Cyclohexylalanine seems to be tolerated equally well as Phe (cf. 6
with 5 and 7). In contrast, strongly negative effects were observed
for tyrosine and 4-pyridylalanine. Replacing Phe with tyrosine
led to a loss in binding to A
q (cf. 3 and 19 with 1)a n d4 -
pyridylalanine was not tolerated at all as it led to a complete loss
of A
q binding for the investigated glycopeptides (see 10, 13
and 16).
Recognition by A
q-restricted T-cell hybridomas
The ability of the designed glycopeptides to induce T-cell
responses was studied using a panel of A
q-restricted T-cell
hybridomas [13,70] specific for 1. Antigen-presenting spleen cells
in the presence of various concentrations of glycopeptides 1–21
were incubated with T-cell hybridomas selected from groups
previously established to have different specificities for the
hydroxyl groups on the GalHyl
264 moiety [8]. Interleukin-2 (IL-
2) secreted into the medium upon recognition of the MHC II/
glycopeptide complex by a T-cell hybridoma was then quantified
in an ELISA. Only glycopeptides that bound to A
q were evaluated
for T-cell recognition.
The 12 glycopeptides evaluated were found to induce different
T-cell response profiles (Table 1 and File S1). Glycopeptides 2 and
4 that bound as strongly to A
q as the non-modified 1 (Table 1), did
also induce medium to strong responses from most of the T-cell
hybridomas. Among the glycopeptides that bound with medium
affinity to A
q (20–55% inhibition), two subgroups could be
distinguished with respect to their T-cell responses. One subgroup
induced weak to medium T-cell responses from most of the
hybridomas (cf. 3, 5, 7 and 14) while another subgroup induced
weak responses usually from only a few of the hybridomas (cf. 6, 8,
9, 11, and 15). The differences in T-cell responses between these
two subgroups could not be linked to different affinity to A
q. For
example, 7 and 9 had similar binding to A
q, but while 7 stimulated
all hybridomas except HCQ.10 moderately, 9 was weakly
recognized only by the HM1R.2 hybridoma. A common feature
of the glycopeptides that bound with medium affinity to A
q, but
induced weak or non-existent T-cell responses, was the presence of
a large side chain in p263, i.e. cyclohexylalanine in 6 and 9 and m-
methylphenylalanine in 8, 11, and 15.
Molecular dynamics simulations of A
q/glycopeptide
complexes
The MD simulations of the A
q/glycopeptide complexes
performed to investigate if structural or dynamic differences of
the presented epitope could be linked to the T-cell responses
were focused on selected glycopeptides (1, 6, 7 and 9).
Glycopeptides 6, 7 and 9 had non-natural amino acids in
p260 and p263 (Figure 5) and comparable affinity for A
q (38–
46% at 100 mM), but displayed different T-cell response
patterns. Glycopeptide 7 generally induced medium T-cell
responses, i.e. responses that correlated well with a somewhat
weaker A
q binding, while both 6 and 9 elicited weak or no T-cell
responses despite having medium affinity for A
q (see Table 1).
The MD simulations revealed that the variation in RMSD values
for the whole A
q/glycopeptide complex was larger for the
glycopeptides that induced medium/strong T-cell responses (1
and 7) than for glycopeptides that induced weak/no T-cell
responses (6 and 9), suggesting that some degree of flexibility was
important for the ability to elicit a T-cell response (File S1).
Interestingly, 6 and 9 also revealed structural differences
Figure 5. Anchor-modified CII259–273 glycopeptides. Glyco-
peptides 2–21 with modified residues at positions p260 and p263 were
synthesized using solid-phase glycopeptide synthesis.
doi:10.1371/journal.pone.0017881.g005
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a 1.2–1.7 A ˚ shorter distance between the Ca of GalHyl
264 and
the A
q protein as compared to the other complexes (File S1).
This indicated that the epitope of 6 presented to the TCRs could
be slightly altered, e.g. by binding of the glycopeptide deeper in
the A
q binding site. Glycopeptide 9 instead had a smaller
variation in RMSD values for the ligand main chain atoms than
glycopeptides 1, 6,a n d7, suggesting that it is more firmly
anchored in the A
q binding site (see File S1).
Binding to DR4 and recognition by DR4-restricted T-cell
hybridomas
Binding to the human DR4 protein was also evaluated using a
competitive ELISA-based assay. All of the designed glycopeptides
(2–21) generated dose-dependent inhibition curves and their
inhibitory effects ranged from 19 to 84% at 500 mM, compared to
72% inhibition for the non-modified glycopeptide 1 (Table 2). The
P1 pocket in the DR4 binding site that accommodates the side
chain of Phe
263 in 1 is a large, deep and mainly lipophilic pocket
(Figure 2b).
As in case for A
q, a linear PLS-regression model correlating the
presence of a specific amino acid in p260 and p263 to the affinity
of the peptides for DR4 was also established (with model statistics
R
2Y of 0.90, Q
2 of 0.55). Permutation experiments again indicated
a low risk of chance-correlations (see File S1).
The regression coefficients of the PLS-model based on DR4
binding data showed that four of the seven amino acids introduced
in p263 were well tolerated (lower part of Figure 6). 3-
cyclohexylalanine, m-methylphenylalanine, 4-fluorophenylalanine,
and Tyr were equally or more beneficial for DR4 binding as
compared to Phe. In contrast, glycopeptides with 4-pyridylalanine
or 4-thiazolylalanine in p263 bound poorly to DR4 (Figure 6 and
Table 2). Amino acids introduced in p260, located in the P-3
position on the flanking region of the binding site (Figure 2), did
not have a large influence on DR4 binding. However, a trend was
noted where larger and more hydrophobic amino acids seemed
beneficial since, for example, the indane derivative improved
binding somewhat (i.e., 20 and 21 in Table 2).
DR4-restricted T-cell responses were evaluated with hybrid-
omas mDR17.2 and hDR11.2 [7,8] specific for 1 using a similar
assay setup as for the A
q system (Table 2). Generally, all
glycopeptides that bound well to DR4 (60–84% inhibition at
500 mM) also produced strong T-cell responses with both
hybridomas. Interestingly, glycopeptides 5, 8, 11, and 15 that
bound strongly to DR4 with affinities comparable to 1 generally
elicited even stronger T-cell responses than 1. Glycopeptides with
thiazolylalanine and 4-pyridylalanine in p263 that bound weakly
to DR4 (19–52% inhibition at 500 mM) generally elicited weaker
T-cell responses and, in particular, the hDR11.2 hybridoma
typically failed to respond.
Table 1. Competitive inhibition of biotinylated CII259–273 binding to the A
q protein by glycopeptides 1–21 and responses by A
q-
restricted T-cell hybridomas.
A
q binding
a T-cell responses
b
Pept. % inhibition (100 mM) % inhibition (500 mM) 22a1-7E HCQ.3 HCQ.10 HM1R.2 HD13.9 HNC.1
1 90619 7 60 ++++ +++++ ++++ ++++++ +++++ +++++
2 87619 5 60 ++++ +++ +++ +++++ ++++ ++++
3 28635 9 63 + +++ + +++ ++ ++
4 86619 4 60 +++ +++++ ++ +++++ ++++ ++
5 29625 8 62 ++ + + ++ +++ ++
6 46617 5 60 22++ + 22
7 39626 7 61 + +++ 2 +++ ++ ++
8 55637 8 61 ++++ + + 22
9 38667 0 61 222+ 22
10 22n.d. n.d. n.d. n.d. n.d. n.d.
11 29635 3 68 ++++ + +2
12 22n.d. n.d. n.d. n.d. n.d. n.d.
13 22n.d. n.d. n.d. n.d. n.d. n.d.
14 20645 0 68 + +++ + +++ ++ 2
15 41617 1 62 22++ ++ 22
16 22n.d. n.d. n.d. n.d. n.d. n.d.
17 22n.d. n.d. n.d. n.d. n.d. n.d.
18 22n.d. n.d. n.d. n.d. n.d. n.d.
19 22n.d. n.d. n.d. n.d. n.d. n.d.
20 22n.d. n.d. n.d. n.d. n.d. n.d.
21 22n.d. n.d. n.d. n.d. n.d. n.d.
aData are expressed as the percentage of biotinylated CII259–273 bound in the absence of competitor glycopeptide (mean values of triplicates 6 one standard
deviation). Glycopeptides assigned with – were classified as inactive (,30% inhibition) in a previous assay and were not included in this assay (see File S1).
bThe magnitude of the T-cell responses were determined from the concentration of antigen required to induce secretion of IL-2 corresponding to 10% of the measured
max response for glycopeptide 1: 2=no response, +=150 mM, ++=30mM, +++=6.0mM, ++++=1.2 mM, +++++=0.24 mM, ++++++=0.0064 mM, n.d.=not
determined. T-cell hybridomas were selected from groups with different specificity for the hydroxyl groups on the GalHyl
264 moiety [8].
doi:10.1371/journal.pone.0017881.t001
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glycopeptides
We investigated the similarities and differences between the
glycopeptides with respect to MHC II binding and recognition by
different T-cell hybridomas. An investigation of the responses
collectively is attractive from a drug (vaccine) development
perspective as the identification of peptides with similar response
patterns in A
q and DR4 systems provides chemical probes that can
be used to link the pharmacodynamic, pharmacokinetic and
toxicity profiles monitored in the A
q mouse model of CIA to DR4-
based models. The latter is more closely associated with
development of RA in humans, in particular from a MHC II
perspective.
A PCA was constructed based on all biological responses and a
score plot is presented in Figure 7a displaying the response
patterns of the glycopeptides, where those that are close to each
other have similar biological activity fingerprints (i.e., similar
affinities for A
q and DR4, and similar T-cell response patterns).
The loading plot in Figure 7b displays the contributions from the
different responses that give rise to the patterns seen in the score
plot. The glycopeptides are differentiated in PC1 mainly by their
different affinity for A
q and their recognition by A
q-restricted T-
cell hybridomas, thereby forming two groups of peptides; binders
(high score values) and non-binders (low score values). From the
loading plot, it is clear that the responses from all A
q-restricted
hybridomas, except HNC.1, are well correlated with the
glycopeptides A
q binding strength. The difference in ability of the
glycopeptides to bind to DR4 and be recognized by DR4-
restricted hybridomas is illustrated in PC2, where active
glycopeptides have a high score-value. Deviations in the
glycopeptides regarding their strength of A
q and DR4 binding
and the magnitude of recognition by the A
q-restricted hybridoma
(e.g. HNC.1) and the DR4-restricted hybridomas (e.g. hDR11.2
and mDR17.2), respectively, were the main information imbedded
in PC3.
Glycopeptide 2 stands out as having similar activity fingerprints
as 1, since it binds well to A
q and DR4 and induces strong T-cell
responses. Glycopeptides with affinity for both proteins included 6,
8 and 9, but these were poorly recognized by the A
q-restricted
hybridomas. Glycopeptides 4 and 7 are A
q-specific, i.e. they both
displayed affinity for A
q but bound poorly to DR4. Among the
glycopeptides with poor binding to A
q, seen in the lower regions of
the score plot in Figure 7a, glycopeptides 18, 21, 20 and 12 were
DR4-specific while 13, 17, 10 and 16 did not bind well to either
protein, nor gave a good T-cell response.
Figure 6. PLS regression coefficient plots. The PLS models were
created by relating glycopeptide properties (expressed via the presence
of a specific amino acid) and their binding capacity to A
q (upper plot)
and DR4 (lower plot) at peptide concentrations of 100 mM and 500 mM,
respectively. A large positive coefficient indicates that the amino acid
was beneficial for a high affinity. Grey bars represent p260 while black
bars represent p263. The indane derivative (2-aminoindane-2-carboxylic
acid) is abbreviated to Aic.
doi:10.1371/journal.pone.0017881.g006
Table 2. Competitive inhibition of biotinylated CLIP binding
to the DR4 protein by glycopeptides 1–21 and responses by
DR4-restricted T-cell hybridomas.
DR4 binding T-cell responses
Pept.
% inhibition
(100 mM)
% inhibition
(500 mM) mDR17.2 hDR11.2
1 39612 7264 +++ +++
2 45657 3 66 ++++ ++++
3 41626 5 64 ++++ +++
4 8643 1 610 +++ 2
5 49647 7 61 +++++ ++++
6 62628 4 64 +++++ +++
7 10614 3466 +++ 2
8 50617 0 63 +++++ ++++
9 44627 5 60 +++++ +++
10 20627 19615 ++ 2
11 51657 6 65 +++++ ++++
12 48627 3 63 ++++ +++
13 22614 5263 +++ +
14 46611 7461 ++++ +++
15 55627 6 62 +++++ ++++
16 18622 23611 + 2
17 20610 26611 ++ 2
18 47696 0 66 +++ +++
19 37688 0 65 +++ +++
20 62628 2 63 ++++ ++
21 44618 4 65 ++++ ++++
aData are expressed as the percentage of biotinylated CLIP bound in the
absence of competitor glycopeptide (mean values of triplicates 6 one
standard deviation).
bThe magnitude of the T-cell responses was determined from the concentration
of antigen required to induce secretion of IL-2 corresponding to 10% of the
measured max response for the native CII259–273 glycopeptide 1: 2=no
response, +=150 mM, ++=30mM, +++=6.0mM, ++++=1.2 mM,
+++++=0.24 mM, ++++++=0.0064 mM. T-cell hybridomas were selected from
groups with different specificity for the hydroxyl groups on the GalHyl
264
moiety.
doi:10.1371/journal.pone.0017881.t002
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In this work a careful design strategy was adopted that
combined the strengths of molecular docking and SMD in order
to accomplish a set of glycopeptides with varying binding affinities
for A
q giving rise to maintained or altered T-cell responses. The
synthesis and biological evaluation of these designed glycopeptides
should give rise to glycopeptides that could be useful in the future
development of a vaccine. Since the design efforts were extensive
one may ask: was this design strategy successful and worth the
efforts? One way to address this question would be to link the
initial aim of the study with the final biological results, in the
context of the design strategy.
The biological evaluation revealed that 11 out of the 20
modified glycopeptides (five different amino acids in p260 and
p263, respectively) bound to A
q with a satisfying spread in the
inhibitory effects ranging from 20 to 87% at 100 mM. These
results should be contemplated while keeping in mind that no
extensive SAR has previously been published for the two
investigated anchor positions (p260 and p263). The presented
SAR analysis of glycopeptides binding to A
q showed that Ile was
the preferred amino acid in p260 since the P1 pocket was sensitive
to all other substitutions. In contrast, the P4 pocket accepted most
of the introduced modifications such as Phe derivatives with an
electron-withdrawing para-fluoro or electron-donating meta-methyl
substituent, 3-cyclohexylalanine, or a thiazole derivative. The A
q
comparative model indicated that the lower half of the P1 and P4
pockets contain a hydrophilic region due to the presence of a Glu
and a Ser residue, respectively. As mentioned earlier, one previous
study has presented that Asp in p263 could bind to A
q [12]. In the
present study, modified glycopeptides with Gln or thiazolylalanine
in p260 had poor affinity for A
q indicating that no favorable
interactions in the hydrophilic regions in P1 were formed. In the
p263 position, on the other hand, glycopeptides with para-
fluorophenyl- and thiazolylalanine showed good affinity for A
q,
while pyridylalanine and tyrosine had no or weak affinity
indicating that the P4 pocket is a potential site for optimization
of electrostatic interactions with the glycopeptides.
As many as 10 modified glycopeptides gave T-cell responses for
more than one A
q restricted hybridoma. We consider this a step
forward in the project as previous information gained regarding
the ternary TCR/pMHC II complexes [8–10,12–15] has revealed
that the system is sensitive to structural modifications of the
(glyco)peptide, with diminished T-cells responses as a conse-
quence. The results regarding T-cell responses and its implication
for vaccination studies are considered in more detail in the final
part of the Discussion.
An interesting outcome of the biological results was the
information regarding DR4 binding and subsequent T-cell
responses. Although docking into DR4 was not included in the
design process, the set of 20 glycopeptides had an inhibitory effect
of 19 to 84% at 500 mM on DR4, and all elicited a T-cell response.
Furthermore, a SAR for p260 and p263 of glycopeptide 1 could be
established for binding to DR4, just as for A
q. Although the P4
pocket of A
q and the P1 pocket of DR4 are similar due to high
sequence identity in the binding sites, different amino acids were
beneficial in the binding to the different proteins. We hypothesize
that the informative results obtained for DR4 could be a direct
effect of the design strategy. Instead of making a stringent focused
library towards optimizing binding to A
q, the design strategy
presented here adopted a more ‘‘loose’’ approach where amino
acids that are less likely to bind A
q and induce a T-cell response
were culled. The ‘‘surviving’’ amino acids were subjected to an
SMD based on physicochemical properties. This appears to have
generated a set of glycopeptides that provided information not
only for A
q (that was used in the design) but also to other related
target proteins, as DR4.
Most of the modifications that we introduced in p263 proved to
be well-tolerated in binding to DR4 and recognition by DR4-
restricted T-cell hybridomas. These findings are consistent with
previous studies where the DR4 P1 pocket was challenged with
several peptides substituted at the MHC anchor position using
Figure 7. Response pattern displayed by the glycopeptides. The response pattern is visualized by score and loading plot from PCA based on
the results from the A
q and DR4 binding and T-cell recognition assays. a) 3D score plot of PC1, PC2 and PC3 displaying similarities and differences
between glycopeptides depending on response patterns. Circles indicate groups among the glycopeptides discussed in the text. b) Loading plot of
the biological responses. A
q and DR4 binding at 100 mM and 500 mM are indicated by red and green spheres, respectively. A
q-restricted hybridomas
22a1-7E, HCQ.3, HCQ.10, HD13.9, HM1R.2 and HNC.1 and DR4-restricted hybridomas mDR17.2 and hDR11.2 at concentrations 150, 30 and 6 mM are
indicated by yellow and blue spheres, respectively. Hybridomas specifically discussed in the text are indicated by their names.
doi:10.1371/journal.pone.0017881.g007
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even larger side chains than those explored in our study were
successfully introduced. However, we noted that Tyr was a good
substitution whereas it has previously been reported to decrease
DR4 affinity 3-fold for CII261–273 [16]. Also we found that the
thiazole and pyridine derivatives exhibited a reduced affinity for
DR4 and a weak or non-existent T-cell response. This is
interesting since the Phe
265 of the human cartilage glycoprotein-
39(263–275), which also is assumed to bind in the DR4 P1 pocket,
has successfully been replaced with both 2-thienylalanine and 3-
pyridylalanine [72].
If we return to the initial question: was the extensive design
strategy based on molecular docking and SMD successful and
worth the efforts? Such question is always difficult to answer, but if
the design efforts are put into perspective of the information
gained for the A
q and DR4 systems, we judge the design successful.
The presented work also resulted in glycopeptides that now are
submitted to vaccination studies (see detailed discussion below).
The current study was conducted on MHC II systems, but it
would be interesting to see the design strategy extended to more
systems to investigate its general applicability.
Variations in T-cell responses elicited by peptide ligands with
modified MHC anchor residues have been described previously
[74–80]. For example, peptides with modified MHC anchor
residues that show decreased affinity for I-E
k have been identified
to function as partial agonists of the TCR [76]. MHC anchor-
modified peptides have also been shown to induce anergy in
polyclonal T-cell populations [77,78], and in one of the studies it
was reported that when administered in vivo to mice, the peptide
reduced both the severity and incidence of EAE as well as being
able to ameliorate an already established disease [77]. In this
study, the strengths of the A
q-restricted T-cell responses elicited by
the modified glycopeptides generally correlated well with the
glycopeptides affinities for A
q. However, some glycopeptides had
similar A
q binding strengths but induced significantly different T-
cell responses. We observed that larger side chains in p263, i.e.
cyclohexylalanine and m-methylphenylalanine, were generally
associated with weak or non-existent T-cell responses despite
medium affinity to A
q.
In the present study MD simulations of selected A
q/glycopep-
tide complexes that displayed similar affinity for A
q but differed in
their T-cell responses revealed structural differences between the
two subgroups. Thus, a lower degree of flexibility in the complex,
or binding of the glycopeptides deeper in the A
q binding site,
appeared to be correlated with weak or non-existent T-cell
responses. Small structural differences has previously been
observed in X-ray crystal structures of E
k/peptide complexes
where substitution of an MHC anchor residue with maintained
MHC binding resulted in a 1000-fold decreased T-cell response
[74]. Various authors have suggested that differences in the rate of
dissociation of the complex formed between the pMHC and the
TCR might be attributable to structural changes in the pMHC
complex that result in altered TCR recognition [81–84].
Generally, faster dissociation rates have been found for interac-
tions that lead to a partially agonistic response while slower
dissociation rates are associated with interactions that lead to a
fully agonistic response. Differences in the rate of dissociation
could also account for the differences in TCR signaling observed
for the modified glycopeptides presented in this study.
Depending on the strategy chosen for a vaccination study using
CIA as a model for RA, glycopeptides with different MHC
binding and T-cell response profiles (cf. Figure 7) will be of
interest. If complexes between the peptide and class II MHC are
used for in vivo vaccination it is most likely beneficial to use a
glycopeptide with high MHC affinity that is also recognized well
by the disease-promoting T cells (e.g. glycopeptide 2 is an
interesting candidate for vaccination in mice expressing A
q, just
like 1). Since the complex does not give a co-stimulatory (second)
signal to the T cells anergy should be induced. Alternatively, such
peptides could have an altered T-cell recognition, which may
address other T-cell clones with regulatory functions. If instead the
glycopeptide alone is used for treatment of an already established
disease, it will bind to class II MHC on professional antigen-
presenting cells that potentially are capable of activating disease-
promoting T cells since they also provide a second, co-stimulatory
signal. It could then be an advantage to use a peptide that binds
weaker to the MHC (e.g. glycopeptide 7 in A
q expressing mice), or
one that binds well but induces a weak or altered T-cell response,
so as not to make an ongoing disease worse. For example, it has
previously been reported that CII-based peptide analogs with
modified MHC anchors that bound poorly to the MHC proteins
can suppress CIA in A
q-expressing mice as well as in DR1- and
DR4-transgenic mice [12,75,85–87]. Especially if the glycopeptide
alone is used for vaccination it would be beneficial to improve its
metabolic stability by e.g. non-natural amino acids to increase the
glycopeptide’s half-life and thereby its therapeutic effect.
Another important issue that one has to consider in the
development of a vaccine for RA is that the results conducted on
mice needs to translate to humans. This challenging task will have
a greater potential of success if one candidate drug shows the same
response pattern in several species, including humans. Hence, it is
important to explore compounds that show both species-specific
and cross-species activity early in the process. For example,
glycopeptides such as 2, which bind well to both A
q (present in
mice) and DR4 (present in humans) and induces strong T-cell
responses, could just like 1 provide an understanding of how
effects obtained in the A
q mouse model translate to the DR4-based
transgenic RA model. We also identified groups of glycopeptides
that bound only to A
q (e.g. 4 and 7), another group that bound
only to DR4 (e.g. 12 and 21). All theses glycopeptides may be
valuable in species-specific studies to elucidate immunological
effects that could further be used in the development of a vaccine
for RA.
Conclusions
In this work, a powerful combination of molecular docking and
SMD was used to study glycopeptide receptor interactions so as to
obtain SAR understanding from a minimized set of glycopeptides.
Selection of the minimized set was done by filtration using
structure-based design (molecular docking) were glycopeptides
likely to fit the receptor binding site with preserved epitope were
identified. This filtration was followed by SMD, where peptides
with diverse physicochemical properties were selected, which in
turn led to a variation in their receptor affinities. The strategy
proved successful when applied to the glycopeptide CII259–273
from type II collagen and led to novel glycopeptides that bound
with variable affinity to the class II MHC A
q and DR4 receptor
proteins. Rational SAR conclusions could be drawn which
revealed the binding preferences of the anchoring pockets in the
two MHC proteins and SAR models were established relating the
glycopeptides’ properties to their affinities for A
q and DR4.
Several glycopeptides induced strong responses in panels of T-cell
hybridomas, selective for complexes of CII259–273 with A
q or
DR4, while others induced weak to medium T-cell responses,
thereby providing a high-level SAR understanding. An analysis of
all of the responses, including binding to A
q and DR4 as well as
recognition by T-cell hybridomas, revealed groups of glycopep-
tides with different response patterns, from which candidates for in
Glycopeptides Used to Investigate Multiresponses
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SAR understanding obtained in this study provides a platform for
design of second-generation glycopeptides, e.g. glycopeptides that
bind to MHC with higher affinity, or that generate fine-tuned T-
cell responses. Finally, it should be highlighted that the design
strategy presented in this work is applicable in the design of new
ligands for any protein-ligand system where a structural model of
the complex is available.
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